Kat Kwiatkowski, PhD, is an Epidemiologist and currently the SVP Clinical Development at Strata Oncology overseeing the functions of Clinical Development & Operations, Medical Affairs, Translational Medicine, and Regulatory. Strata is a precision oncology company committed to accelerating the impact of precision medicine for patients with cancer. Kat led the design and build of two of the largest prospective cohort studies in the world including the Strata Trial (NGS) and the Sentinel Trial (ctDNA recurrence & treatment monitoring). These studies inform the newly designed StrataPATH study, an interventional therapeutic study to advance biomarker hypotheses. Prior to Strata, Kat worked in various Clinical Development roles in both diagnostics and pharma including Affymetrix where she and team were the first to receive FDA clearance for the first whole genome microarray in cytogenetics. Kat is passionate about helping cancer patients get the best personalized care.
Precision medicine is among the key contributors in progressing cancer survivorship. However, biomarker testing, which is critical to enabling precision medicine treatments, is below guideline recommendations due to various factors. The session will discuss these barriers, as well as bringing tangible and sustainable solutions to patients with cancer through collaboration.